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against a new therapeutic agent?
Mark A Wainberg1*, Thibault Mesplède2 and Francois Raffi3Abstract
Background: The HIV integrase inhibitor, Dolutegravir (DTG), was recently approved by the Food and Drug
Administration in the United States and is the only HIV drug that has not selected for resistance mutations in the
clinic when used as part of first-line therapy. This has led to speculation that DTG might have a higher genetic
barrier for the development of drug resistance than the other compounds that are used in therapy.
Discussion: In this Opinion article, we speculate that this is due to greatly diminished replication capacity on the
part of viruses that might become resistant to DTG when the drug is used in initial therapy and that DTG might be
able to be used in HIV prevention and eradication strategies. We also note that no compensatory mutation that
might restore viral replication fitness to HIV in the aftermath of the appearance of a single drug resistance mutation
has yet to be observed.
Summary: DTG is a valuable addition to the anti-HIV armamentarium of drugs and its long-term utility may
potentially exceed its obvious use in treatment of HIV disease.
Keywords: Human immunodeficiency virus type 1, Integrase inhibitors, Antiretroviral therapy, Dolutegravir,
HIV prevention strategies, Viral fitness, Drug resistanceBackground
The current standard of care for treatment of HIV infection
is the use of three antiretroviral (ARV) drugs in combin-
ation, with more and more simplified regimens becoming
available. Since the introduction of triple ARV therapy in
1996, the rates of success of therapy, as indicated by sup-
pression of plasma viremia to levels below a cut-off of 50
copies of viral RNA/ml, have increased to almost 90% [1].
This has happened for several major reasons. 1) The drugs
used in therapy are now more potent and have longer
half-lives than the compounds that were in use only
15 years ago. 2) Dosing regimens have become simplified,
often because of the use of co-formulations, some of which
only need to be taken once-daily, and this has greatly
enhanced rates of adherence to ARV regimens. 3) Drug
regimens have become far less toxic and more tolerable
over time, and this has also promoted adherence as well as
diminished the likelihood of development of HIV drug re-
sistance against the components of ARV regimens [2,3].* Correspondence: mark.wainberg@mcgill.ca
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2013The above notwithstanding, the use of ARVs in first
line regimens has always been associated with some degree
of treatment failure and drug resistance. Indeed, scientists
have meticulously catalogued a wide array of drug resist-
ance mutations that are located within each of the reverse
transcriptase, protease and integrase of HIV-1 that are the
targets of HIV therapy, and have documented how each
of these mutations may lead to diminished likelihood of a
favorable clinical response to each ARV, both in cell culture
and in therapy [1]. The phase III clinical trials that led to
the approval of each of the ARVs now used for therapy also
provided valuable information on the types of viral muta-
tions that were most likely to be identified in the event of
treatment failure. This included studies on several of the
most recent ARVs to have gained approval by regulatory
agencies, most notably raltegravir (RAL) and elvitegravir
(EVG) that are members of the integrase inhibitor family of
drugs [4-9]. Now, however, a third member of this family,
termed dolutegravir (DTG), has been studied in phase III
clinical trials and has yielded the most robust results ever
obtained in HIV registrational clinical trials [1,10,11]. First,
approximately 88% of patients who received DTG together
with two members of the nucleoside reverse-transcriptaseral Ltd. This is an Open Access article distributed under the terms of the Creative
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suppression of viral load to <50 copies RNA/ml. Perhaps,
more importantly, none of the individuals in the studies
could be shown to possess a single drug resistance-related
mutation. This is despite the fact that some patients in
the trials, perhaps for reasons of non-adherence, did fail
therapy and possessed detectable levels of viral load in
plasma [9-11]. The other compounds employed were
co-formulations of either lamivudine (3TC)/abacavir or
emtricitabine (FTC)/tenofovir.
The viral fitness hypothesis
One hypothesis that has been advanced to explain these
results is that viruses that become resistant to DTG may
be relatively replication incapacitated and may be un-
likely to efficiently grow or to be detected in patient
samples [12]. Indeed, it has been shown that DTG can
select a mutation at position R263K in the integrase
gene in tissue culture and that this mutation diminishes
both viral replication capacity as well as the enzymatic
activity of the integrase enzyme [13]. This is in itself not
unusual, as similar results had also been obtained with
the two other approved integrase inhibitors RAL and EVG
[4]. However, in the case of the latter two compounds, the
presence of an initial mutation was often quickly followed
by the appearance of a second substitution that had the
dual effect of increasing the level of drug resistance, often
to a level that might preclude any further clinical benefit
from the drug, while simultaneously restoring viral repli-
cation capacity to normal levels (Figure 1, Table 1). In con-
trast, the secondary mutations that were selected by DTG
only modestly increased overall levels of resistance against
the drug but simultaneously impacted even more adversely
on the ability of the virus to replicate. This was also
reflected in a further diminution in the activity of the
HIV integrase enzyme [12,13].
The concept that secondary and/or tertiary drug resist-
ance mutations may play a compensatory role in regard to
replication is not unique to HIV. Indeed, similar findings
have been documented for bacteria that are resistant to
numerous antibiotics as well as for other viruses that
display resistance against specific viral agents. In the
case of HIV, compensatory mutations that simultaneously
augment viral replication while increasing overall levels
of drug resistance have been documented for members
of each of the NRTI and non-nucleoside RT inhibitor
(NNRTI) families of drugs as well as for protease inhibitors
(PIs) and entry inhibitors [2]. Although treatment failure in
the absence of resistance mutations in the viral protease
gene has been described, this is widely attributed to the fact
that cleavage site mutations in the Gag and Gag-pol
substrates of the protease enzyme are known to occur,
and such mutations, although not well characterized,
are known to confer resistance to PIs.The fact that no resistance mutation has yet been identi-
fied for DTG in treatment-naïve patients represents a
unique observation. Moreover, this finding is bolstered
by the results of tissue culture selection experiments
with DTG that have only yielded two distinct mutations
that are associated with diminished viral replicative capacity
but never a third compensatory mutation, despite efforts
that have persisted over almost three years [12]. Therefore,
an added benefit of using DTG in first-line therapy may be
that viruses that do contain R263K will not be transmitted
or that this mutation will revert if viral transmission does
take place, due to low replication fitness. Such reversion
has been reported for HIV variants that contain the M184V
mutation that is associated with resistance to 3TC and
FTC and that also impairs HIV fitness. It may turn out,
as an example, that the use of DTG in Treatment as
Prevention (TasP) protocols, whereby reductions in viral
load on a population level can be expected to result in
diminished rates of HIV transmission, will obviate con-
cerns about the development of resistance to the drugs
used in this strategy.
This raises several issues. First, what if it turns out that
viruses that are resistant to DTG cannot be compensated
by additional mutations within Integrase and that such vi-
ruses are at a severe replication disadvantage in compari-
son with wild-type viruses. This result would take on even
greater significance should it turn out that DTG can retain
clinically significant antiviral activity, despite the presence
of one or two mutations associated with drug resistance.
In fact, such a scenario is suggested by the fact that the
level of resistance conferred against DTG by the com-
bination of two mutations within Integrase is relatively
slight, that is, <10-fold. Furthermore, biochemical re-
sults have shown that the ability of DTG to bind to the
Integrase enzyme and remain associated with it is very
long, that is, >36 hours, and that the R263K mutation
only diminishes this level of binding by about 50% [14].
While this may seem substantial, the reality is that this is
still longer than the binding affinity half-life of RAL for the
wild-type integrase enzyme. Could these findings in fact
suggest that the development of resistance against DTG
might at the end turn out to provide a unique virologic
and clinical benefit?
One way to test this notion might be to conduct a study
in which DTG is employed as monotherapy in treatment
inexperienced subjects. Should it turn out that the results
obtained are similar to those observed in the phase III
clinical trials, a partial validation of the hypothesis to
explain the absence of resistance in the phase III trials
will have been provided. Of course, such a monotherapy
study would need to be accompanied by intense virologic
monitoring for resistance mutations, which should include
the use of ultrasensitive sequencing methods for identifi-
cation of DTG resistance mutations in both the RNA of
Figure 1 Potential evolution of HIV-1 following therapy of previously treatment-naïve individuals with integrase inhibitors. In rare
cases, the emergence of resistance mutations in patients treated with raltegravir or elvitegravir can lead to virological failure (left). Virological
failure with resistance mutations in treatment-naïve patients treated with dolutegravir has not been reported (right).
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peripheral blood mononuclear cells.
In one sense, some clinical validation of the significance
of the R263K mutation has already been obtained. Notably,
the SAILING-clinical trial compared the use of RAL against
DTG in treatment-experienced patients who had under-
gone previous failures of their therapeutic regimens but
who had never before been treated with an integrase
inhibitor [15]. Many of these patients possessed drug re-
sistance mutations that might have compromised the
anti-viral activity of multiple ARVs in the regimens thatthey received in the SAILING study, but not of the inte-
grase inhibitors. The results of the trial showed that DTG
was superior to RAL at suppression of viral load in this
population. Moreover, the only drug resistance mutation to
have appeared in only very few patients in the DTG arm
of the study was R263K. Although this cautions that the
development of resistance to DTG in drug-naïve patients
may be possible, it should be noted that the patients who
received DTG and who possessed the R263K mutation
continued to do very well from a clinical perspective over
the 48-week period of the trial. Failure on the RAL arm of






























INSTIs, Integrase Strand Transfer Inhibitors.
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are associated with resistance to the latter drug.
Based on these observations, a strong case can be made
that DTG can be considered as a drug of choice for patients
entering therapy for the first time. Although the develop-
ment of R263K and a subsequent mutation may not confer
any deleterious effect in regard to patient management, it
is clear that the prior development of mutations associated
with resistance against RAL or EVG may compromise the
clinical performance of DTG. Each of the Viking I, II and
III studies has now shown that DTG can be successfully
used to salvage significant numbers of patients who first
were treated with RAL or EVG and who failed those
regimens [16]. However, a successful clinical outcome
was not accomplished in many cases, and there seems
little doubt that many patients who first fail RAL- or
EVG-based regimens may not be able to remain durably
suppressed virologically when treated with DTG as partof a second-line regimen. The argument that integrase
inhibitors can or should always be used sequentially,
beginning with a different drug, such as RAL or EVG,
and then switching to DTG, may not be sustainable.
Future directions
A more intriguing question, however, is what will happen
if patients do as well on DTG monotherapy as on triple
therapy, despite the presence of the R263K mutation.
Would clinicians then be willing to entertain the notion of
withholding DTG from therapy at a certain point as part
of a structured treatment interruption? In this scenario, it
is conceivable that the impaired viruses containing DTG
resistance mutations would not be able to grow out. What
would then become of the wild-type viruses that had be-
come archived after infecting the patient in the first place?
Presumably, a high proportion of such viruses would begin
to replicate following activation of latent reservoirs in the
same manner as has been observed following treatment
interruption in other trials. However, re-initiation of DTG
monotherapy might then convert these wild-type viruses
into DTG-resistant attenuated forms. Is it conceivable that
a number of cycles of DTG treatment interruption followed
by re-initiation of DTG monotherapy could convert all the
HIV in the body to a replication impaired form? Could
such an approach lead to a functional cure of HIV disease
if all residual viruses were significantly impaired in viral
replication and if further compensatory mutations were
unable to develop?
To be sure, these are the types of concepts that should
ideally first be studied in animal models such as rhesus
macaques that are infected by simian immunodeficiency
virus (SIV) or humanized mice that are infected by HIV.
However, some clinicians have experimented with mono-
therapy in the past and are likely to do so again. Moreover,
there is a probability that this will happen with DTG after
it is approved by regulatory agencies, when there are fewer
limitations on the conduct of small-scale clinical trials of
this type. There is a likelihood that such studies will be
ethically justifiable, if a case can be made for benefits that
exceed those of the suppression of viral load.
Discussion
One last issue relates to possible implications for the
companies that plan to sell DTG if this drug is successfully
used in either HIV cure or prevention strategies. For
one thing, the cost of DTG has already been established
in virtually all countries at a level that is based on the
price of other currently approved ARVs and the expectation
that patients will need to take DTG on a chronic basis over
many years. Although noone would want the cost of DTG
to be increased, the reality is that the cost of treatment with
potentially curative drugs for hepatitis C virus is likely
to be at least five times that of DTG. In addition, the
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for HIV available as expeditiously as possible for people
in developing countries will be difficult to withstand. Of
course, as stated above, these scenarios may only apply
to patients who have not previously been treated with
any integrase inhibitor and for whom the viral fitness
hypothesis following use of DTG makes good sense.
Summary
Dolutegravir is a welcome addition to the anti-HIV arma-
mentarium of drugs and has shown unprecedented benefit
to patients who have taken it as part of a first-line
therapeutic regimen. Until now, no resistance mutation has
developed either against DTG or any of the drugs used
together with it in first-line therapy, and supportive tis-
sue culture data have shown that the development of an
initial HIV resistance mutation against DTG may result in
a virus with greatly diminished replicative fitness. It is pos-
sible that DTG will lend itself to use in a variety of HIV
prevention strategies, such as Treatment as Prevention,
and that it might possibly also be used in efforts designed
to accomplish a cure for HIV infection.
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